Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | CDK7 | P50613 | 3/20 | 0.41 |
| ▸ | CCNH | P51946 | 2/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 15/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18073036 | 0.89 | CDK2 (0.53) | CDK2CCNE1CDK7CCNHMNAT1 | |
| SCHEMBL19912802 | 0.81 | CDK2 (0.40) | CDK2CCNE1CDK7CCNHMNAT1 | |
| SCHEMBL19896531 | 0.80 | BCDIN3D (0.45) | CDK2CDK7CCNHMNAT1CDK9 | |
| SCHEMBL19912803 | 0.78 | CDK2 (0.60) | CDK2CDK7CCNHMNAT1CDK9 | |
| SCHEMBL21484228 | 0.77 | ADORA1 (0.34) | CDK2CCNE1CDK7CCNHMNAT1 | |
| SCHEMBL16659551 | 0.77 | CDK2 (0.36) | CDK2CCNE1CDK7CCNHCDK9 | |
| SCHEMBL23352057 | 0.76 | ADORA1 (0.39) | CDK2CCNE1CDK7CCNHMNAT1 | |
| SCHEMBL21481503 | 0.76 | ADORA1 (0.39) | CDK2CCNE1CDK7CCNHMNAT1 | |
| SCHEMBL12584690 | 0.75 | CSNK2B (0.39) | ADORA1CSNK2A1TTK | |
| SCHEMBL19912800 | 0.74 | CDK9 (0.47) | CDK2CCNE1CDK7CCNHCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | CDK2 13/4885CCNE1 33/4885CDK7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.